Information about Zofran.

32 mg dosage of Zofran previously removed from market due to cardiac risks

March 6th, 2015

In 2012, the United States Food and Drug Administration pulled the 32 milligram intravenous dosage of Zofran due to increased and serious cardiac risks. Zofran has since been associated with an increased risk of other severe side effects, including birth defects among children born to women who use Zofran during pregnancy.

Zofran is an antinausea drug prescribed most commonly to patients who are undergoing cancer treatments such as chemotherapy. Some doctors have also prescribed the drug to treat morning sickness, though the drug has not been approved for such uses, and manufacturer GlaxoSmithKline has previously paid billions of dollars to settle lawsuits alleging the company illegally promoted the drug.

Patients have begun filing Zofran lawsuits against GSK after studies have linked the drug to severe birth defects. Zofran birth defects include musculoskeletal anomalies, jaundice, heart murmurs and other heart defects.


Contact Us Today for a Free Consultation.

I am currently represented by an attorney.
*Required fields